Abingdon Health PLC
LSE:ABDX

Watchlist Manager
Abingdon Health PLC Logo
Abingdon Health PLC
LSE:ABDX
Watchlist
Price: 6.75 GBX Market Closed
Market Cap: 16.9m GBX

Abingdon Health PLC
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Abingdon Health PLC
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Abingdon Health PLC
LSE:ABDX
Net Income (Common)
-ÂŁ3.4m
CAGR 3-Years
46%
CAGR 5-Years
0%
CAGR 10-Years
N/A
ConvaTec Group PLC
LSE:CTEC
Net Income (Common)
$216.7m
CAGR 3-Years
39%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Tristel PLC
LSE:TSTL
Net Income (Common)
ÂŁ6.6m
CAGR 3-Years
89%
CAGR 5-Years
5%
CAGR 10-Years
12%
Inspecs Group PLC
LSE:SPEC
Net Income (Common)
-ÂŁ4.6m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Advanced Medical Solutions Group PLC
LSE:AMS
Net Income (Common)
ÂŁ9.1m
CAGR 3-Years
-21%
CAGR 5-Years
-8%
CAGR 10-Years
-4%
Rua Life Sciences PLC
LSE:RUA
Net Income (Common)
ÂŁ1k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Abingdon Health PLC
Glance View

Market Cap
16.9m GBX
Industry
Health Care

Abingdon Health Plc develops, manufactures and commercializes immunoassay tests and reader systems. The company is headquartered in York, North Yorkshire and currently employs 151 full-time employees. The company went IPO on 2020-12-15. The firm operates through three segments: Contract Development, Contract Manufacturing and Product Sales. The Contract Development segment comprises development work for third parties and is recognized over time based on a proportion of completion. The Contract Manufacturing segment comprises contract development and manufacturing activities. The Product Sales segment comprises the sale of ABC-19, pocket diagnostic products, progressive rod cone degeneration (PCRD) tests and antibodies for research use. Its products also include Seralite, which includes Free Light Chain (FLC) Serum. The Company’s geographical market include the United Kingdom, the United States/Canada, rest of world (ROW).

ABDX Intrinsic Value
11.92 GBX
Undervaluation 43%
Intrinsic Value
Price

See Also

What is Abingdon Health PLC's Net Income (Common)?
Net Income (Common)
-3.4m GBP

Based on the financial report for Jun 30, 2025, Abingdon Health PLC's Net Income (Common) amounts to -3.4m GBP.

What is Abingdon Health PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
0%

Over the last year, the Net Income (Common) growth was -169%. The average annual Net Income (Common) growth rates for Abingdon Health PLC have been 46% over the past three years .

Back to Top